Australian-headquartered medicinal cannabis company, Cannim, has announced the completion of the first-ever legal commercial export of Jamaican cannabis flower to Germany.
Germany is one of the world’s most significant medicinal cannabis markets, and Cannim’s Chief Commercial Officer Stuart Marsh said this announcement was a key step towards achieving Cannim’s mission to become a global leader in the medicinal and wellness cannabis sectors.
“Germany represents a huge opportunity for Cannim, and our ability to cultivate high quality, medical-grade Jamaican cannabis that meets the strict standards of the German Pharmacopoeia is testament to the professionalism of our teams in Jamaica and Australia,” Marsh said.
“The support we have received from all levels of the Jamaican government and its agencies and the rigour of Jamaica’s Cannabis Licensing Authority (CLA) in ensuring Jamaica’s industry complies with international treaty obligations have been essential in securing Jamaica’s entry to this global arena. In particular, we’d like to acknowledge the Government’s and CLA’s willingness to expedite the improvement of interim regulations and timely processes to drive Jamaica’s ability to effectively compete on the world stage,” he added.
Minister of Industry, Investment and Commerce Audley Shaw was similarly enthused by the landmark achievement.
“Jamaica has long had a rich history with cannabis and we are proud to have been able to support the industry and Cannim in achieving this pioneering export to Germany,” Shaw said.
“We are excited to finally be able to start satisfying global demand for the finest Jamaican-grown medicinal cannabis products,” the elder statesman added.
The initial shipment of high-THC cannabis flowers was grown on Cannim’s 500-acre farm in Jamaica, representing the first batch of an ongoing supply, with significant quantities of the product ready to be released into Germany over the coming months.
Cannim has formed a strong partnership with Cantourage, one of Europe’s leading medical cannabis companies, and will use Cantourage’s “Fast Track Access” platform to enter European medical markets.
Philip Schetter, CEO of Cantourage, recognised the significance of the development.
“This is an exciting milestone for the rapidly expanding medicinal cannabis sector in Germany,” Schetter said.
“The local market has been growing for some time, but this is the first time we have been able to supply the highest quality products processed from genuine Jamaican cannabis flower,” Schetter began.
“Cantourage places great value on natural products which amplify the benefits for German patients, and this partnership opens up access to a new source with an established reputation for ideal growing conditions. Our partnership with Cannim offers us an unprecedented opportunity to bring medical cannabis from Jamaica, which is known for its ideal growing conditions, into the fast-growing European medical cannabis market for the first time,” he continued.
“It is an important step in the development of this still nascent industry,” the Cantourage CEO added.
Established in 2017, Cannim was founded on the vision of bringing the benefits of medicinal cannabis to the world, moving the trade from the darkness into the light. This long-term vision is integral to Cannim’s approach to improving its consumers’ health and wellness – delivering ‘Better Balanced Bodies’ and establishing world-leading medicinal and wellness cannabis brands.
Cannim has invested in farms, EU-GMP (Good Manufacturing Practice)-compliant production facilities, and research programs in Jamaica and Australia, utilising expertise in major global markets including Israel, Jamaica, the USA, the UK and Australia. It operates alongside an international network of EU GMP manufacturers and channels to market.